ORIC Pharmaceuticals, Inc. announced initial data for its PRC2 inhibitor ORIC-944, operational highlights for 2023, and anticipated upcoming milestones. As of December 10, 2023, the initial Phase 1b monotherapy data for ORIC-944, a potent and selective allosteric inhibitor of PRC2, in patients with metastatic prostate cancer demonstrated: Potential best-in-class drug properties, including clinical half-life consistent with preclinical prediction of >10 hours, which is superior to other PRC2 inhibitors and supports QD dosing; No signs of CYP autoinduction that is seen with first-generation PRC2 inhibitors; Robust target engagement with maximal decrease (=75%) in H3K27me3 in monocytes from peripheral blood samples at doses as low as 200 mg QD, with low inter-patient variability; and Favorable safety with only grade 1 and 2 treatment-related adverse events at dose levels corresponding with strong target engagement. Emerging profile with superior drug properties support advancement into combination development in prostate cancer with AR inhibitor(s).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.6 USD | -0.10% | +2.89% | +4.35% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.35% | 647M | |
+2.93% | 108B | |
+7.02% | 23.46B | |
-14.60% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-8.83% | 17.19B | |
+5.51% | 13.99B | |
+37.49% | 12.53B | |
+329.39% | 8.81B |
- Stock Market
- Equities
- ORIC Stock
- News ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals, Inc. Provides Initial Phase 1B Data for Oric-944